Effect of food on the pharmacokinetic profile of trans-resveratrol

International Journal of Clinical Pharmacology and Therapeutics

Volumn 46, Issue 11, 2008, Pages 564-570

  Vaz da Silva, M ^a,b   Loureiro, A I ^a   Falcao, A ^c   Nunes, T ^a   Rocha, J F ^a   Fernandes Lopes, C ^a   Soares, E ^a   Wright, L ^a   Almeida, L ^a,b   Soares da Silva, P ^a,b  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

^b University of Porto   (Portugal)

^c Biocant   (Portugal)

Author keywords

Bio availability; Food effect; Food interaction; Trans resveratrol

Indexed keywords

PHYTOALEXIN; TRANSRESVERATROL; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIET RESTRICTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; FOOD; FOOD DRUG INTERACTION; HUMAN; HUMAN EXPERIMENT; LIPID DIET; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 56749153720     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP46564     Document Type: Article

References (15)

1. Anekonda TS. Resveratrol - a boon for treating Alzheimer's disease? Brain Res Rev. 2006; 52: 3 16-326.
2. Bhat KPL, Kosmeder JW, 2nd, Pezzuto JM. Biological effects of resveratrol. Antioxid Redox Signal. 2001; 3: 1041-1064.
3. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, Steward WP, Brenner DE. Phase I dose escalation pharmacokinetic study in healthy volunteers Of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomark Prev. 2007; 16: 1246-1252.
4. Bruno R, Ghisolfi L, Priulla M, Nicolin A, Bertelli A. Wine and tumors: study of resveratrol. Drugs Exp Clin Res. 2003; 29: 257-261.
5. Chow S-C, Wang H. On sample size calculation in bioequivalence trials. J Pharmacokinet Pharmacodyn. 2001; 28: 155-169.
6. de la Lastra CA, Villegas I. Resveratrol as an antiinflammatory and antiaging agent: mechanisms and clinical implications. Mol Nutr Food Res. 2005; 49: 405-430.
7. EMEA/CPMP. Committee for Proprietary Medicinal Products (CPMP): Note for guidance on the investigation of bioavailability and bioequivalence. CPMP/EWP/1401/98. London: The European Agency for the Evaluation of Medicinal Products (EMEA); 2001.
8. FDA/CDER. Guidance for Industry (Draft): Food-effect bioavailability and fed bioequivalence studies: Study design, data analysis, and labeling, Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2001.
9. FDA/CDER. Guidance for Industry: Bioavailability and bioequivalence studies for orally administered drug products - General considerations. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research; 2003.
10. Fremont L. Biological effects of resveratrol. Life Sci. 2000; 66: 663-673.
11. Kopp P. Resveratrol, a phytoestrogen found in red wine. A possible explanation for the conundrum of the "French paradox?" Eur J Endocrinol. 1998; 138: 619-620.
12. Vitaglione P, Sforza S, Galaverna G, Ghidini C, Caporaso N, Vescovi PP, Fogliano V, Marchelli R. Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res. 2005; 49: 495-504.
13. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Ralle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 2004; 32: 1377-1382.
14. Wenzel E, Somoza V. Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res. 2005; 49: 472-481.
15. Zhuang H, Kim YS, Koehler RC, Dore S. Potential mechanism by which resveratrol, a red wine constituent, protects neurons. Ann NY Acad Sci. 2003; 993: 276-288.